Medicine Australia's Board Changes
This article was originally published in Scrip
Managing director of Boehringer Ingelheim Australia, Wes Cook, has been appointed Medicines Australia's interim-chair, following the retirement of Martin Cross. In addition to this, the new board was also announced at the company's annual general meeting.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.